Shots:

• With the closure of the transaction- Oncternal Therapeutics will be listed on Nasdaq under the ticker ONCT
• Oncternal’s stockholders will hold 75% of the shares of combined company and GTx will retain 25% of shares. GTx stockholders will receive 50% non-transferable contingent value rights (CVR) from the grant- sale or transfer of rights to SARD
• The newly merged company have strong Octernal’s oncology portfolio with GTx’s Selective Androgen Receptor Degrader (SARD) technology for castration-resistant prostate cancer

Ref: Oncternal | Image: GMP news